Market News & Trends
Novozymes Biopharma Enables Stable Formulation of Serendex Pharmaceutical’s Drug
Denmark-based Serendex Pharmaceuticals recently announced they will initiate Phase I clinical trials for their Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) drug candidate, Molgradex. The drug…
Pluristem Announces Significant Advancement to its Clinical Development Plan
Pluristem Therapeutics Inc. (PSTI) recently announced a significant advancement to its clinical development plan: the PLX cell program in critical limb ischemia has been selected…
Eleven Biotherapeutics Announces Top-Line Results From Pivotal Phase III Study
Eleven Biotherapeutics, Inc. recently announced top-line results from the OASIS study, the company’s first pivotal Phase III study of its lead drug candidate, EBI-005, in…
First Patient Dosed in Phase II Study of Tipifarnib
Kura Oncology, Inc. recently announced that the first patient has been dosed in the Phase II clinical trial of tipifarnib in patients with locally advanced…
Selecta Biosciences Makes Two Major Announcements
Selecta Biosciences, Inc. recently announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to…
Pfizer Acquires Minority Interest in Biopharmaceutical Company; Secures Option to Acquire
AM-Pharma B.V. and Pfizer Inc. recently announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the…
BASF to Focus Pharmaceutical Ingredients Business on its Core Expertise
BASF plans to focus its pharmaceutical ingredients and services business within the Nutrition & Health division on its core expertise in pharmaceutical excipients. To implement…
Lilly & Sanford-Burnham Announce Major Collaboration
Eli Lilly and Company and Sanford-Burnham Medical Research Institute recently announced they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham, a non-profit…
Meggle Introduces World’s First Triple Compound
Meggle recently announced the introduction of a new high-functionality excipient (HFE) CombiLac®, a lactose-based, co-processed excipient, specifically designed to ease oral solid dosage form development…
Cortendo Adds Two Late-Stage Assets & Announces Related $33.2 Million Financing
Cortendo AB recently announced it has entered into an agreement to acquire Aspireo Pharmaceuticals’ Somatoprim (DG3173), an investigational compound being studied for the treatment of…
Strategic Product Lifecycle Management Through Secondary Packaging
Developing and launching a new drug is often a burden on resources, time and money. Pharmaceutical and biotech companies can only afford the…
bluebird bio Announces Global Regulatory Strategy for Gene Therapy
bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, recently…
West Bolsters R&D Strategy With Global Site Expansions & Upgrades
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative packaging components and drug delivery systems, today announced a multi-year investment as part of…
XenoTech Accepting Global Scientific Achievement Award Nominations for 2015
Lenexa, KS (May 18, 2015) – XenoTech, a division of Sekisui, is accepting nominations for the 2015 XenoTech Global Scientific Achievement Award. This award is…
Scientists Identify Promising New Melanoma Treatment Strategy
Scientists looking to better understand the mechanisms behind the origin and spread of melanoma tumors have uncovered a possible role for a decades-old antibacterial agent…
Study Finds EMD Millipore's Strat-M Synthetic Membrane Study Results
EMD Millipore, recently announced publication of a study showing that its Strat-M synthetic membrane predicts skin permeation of chemical compounds during in vitro transdermal diffusion…
PlasmaTech Biopharmaceuticals Announces Major Acquisition
PlasmaTech Biopharmaceuticals, Inc. recently announced it has entered into a definitive agreement to acquire Abeona Therapeutics, a company engaged in the development and commercialization of…
Capsugel Extends Inhaled Biotherapeutics Delivery Capability
Capsugel recently announced it has manufactured Phase II clinical trial supplies for a dry powder inhalation (DPI) formulation that efficiently delivers biotherapeutics to the lung.…
Vcaps® Plus Capsules: A New HPMC Capsule for Optimum Formulation of Pharmaceutical Dosage Forms
abstract Hypromellose (HPMC) capsules were originally formulated with a secondary gelling agent. This agent can delay dissolution in some circumstances and lead to unwanted issues…
N-of-One Signs Business partner Agreement With Affymetrix
N-of-One, Inc. recently announced it has signed a business partner agreement with Affymetrix,a leading provider of DNA microarrays. Under this agreement, N-of-One will provide copy…
2025 - 5 - Gattefosse - 250x250